Kymab racks up $100 Series C

UK-based Kymab, a developer of fully humanized antibodies that treats challenging diseases, has raised $100 million in Series C funding. ORI Healthcare Fund LP led the round with participation from other investors that included Wellcome Trust, Bill & Melinda Gates Foundation, Shenzhen Hepalink Pharmaceutical Co Ltd, Malin Corporation plc, CF Woodford Equity Income Fund and Woodford Patient Capital plc.

North AmericaUSBriefs